Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus IOPAMIDOL 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus IOPAMIDOL 300.
HYPAQUE SODIUM 20% vs IOPAMIDOL-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Iopamidol is a nonionic, water-soluble iodinated contrast agent that attenuates X-rays, thereby enhancing radiographic visualization of vascular structures and organs. It does not bind to receptors and has no significant pharmacological activity.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., 1-2 mL/kg for CT, up to 50-100 mL for angiography) up to a maximum of 200 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min). In moderate renal impairment it extends to 3-5 hours; in severe renal impairment (CrCl <30 mL/min) it can exceed 30 hours, prolonging diagnostic window.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Primarily renal excretion of intact drug via glomerular filtration; >90% excreted unchanged in urine within 24 hours. Less than 1% fecal or biliary elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent